Logo image
Back
An improved method of delivering a sclerosing agent for the treatment of malignant pleural effusion
Journal article   Open access   Peer reviewed

An improved method of delivering a sclerosing agent for the treatment of malignant pleural effusion

Tim N Beck, Alexander Y Deneka, Louis Chai, Colin Kanach, Priya Johal, Nicolas J Alvarez, Yanis Boumber, Erica A Golemis and Glenn W Laub
BMC cancer, v 19(1), pp 614-614
24 Jun 2019
DOI: https://doi.org/10.1186/s12885-019-5777-z
PMID: 31234819
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1186/s12885-019-5777-zView
Published, Version of Record (VoR)CC BY V4.0,  Open

Abstract

Animals Carcinoma, Lewis Lung - complications Disease Models, Animal Drug Delivery Systems - methods Female Fibrosis - diagnosis Hydrogel, Polyethylene Glycol Dimethacrylate - chemistry Lung - pathology Lung Volume Measurements Male Mice Mice, Inbred C57BL Pleura - pathology Pleural Effusion, Malignant - etiology Pleural Effusion, Malignant - therapy Pleurodesis - methods Sclerosing Solutions - administration & dosage Sclerosing Solutions - therapeutic use Talc - administration & dosage Talc - therapeutic use Transition Temperature Treatment Outcome
Malignant pleural effusion (MPE) is a devastating sequela associated with cancer. Talc pleurodesis is a common treatment strategy for MPE but has been estimated to be unsuccessful in up to 20-50% of patients. Clinical failure of talc pleurodesis is thought to be due to poor dispersion. This monograph reports the development of a foam delivery system designed to more effectively coat the pleural cavity. C57BL/6 mice were injected with Lewis lung carcinoma (LL/2) cells intrapleurally to induce MPE. The mice then received either normal saline (NS) control, foam control (F), talc slurry (TS, 2 mg/g) or talc foam (TF, 2 mg/g). Airspace volume was evaluated by CT, lungs/pleura were collected, and percent fibrosis was determined. The TF group had significantly better survival than the TS group (21 vs 13.5 days, p < 0.0001). The average effusion volume was less in the talc groups compared to the control group (140 vs 628 μL, p < 0.001). TF induced significant lung fibrosis (p < 0.01), similar to TS. On CT, TF significantly (p < 0.05) reduced loss of right lung volume (by 30-40%) compared to the control group. This was not seen with TS (p > 0.05). This report describes using a novel talc foam delivery system for the treatment of MPE. In the LL/2 model, mice treated with the TF had better survival outcomes and less reduction of lung volume than mice treated with the standard of care TS. These data provide support for translational efforts to move talc foam from animal models into clinical trials.

Metrics

12 Record Views
4 citations in Web of Science
3 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Oncology
Logo image